Tazarotene is a retinoid indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement, among other approved uses. It is available as gel, cream and foam for topical and cutaneous use. MedsAcross supplies Tazarotene for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
TAZORAC ® Gel, 0.05% and 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement. TAZORAC Gel, 0.1% is indicated for the topical treatment of mild to moderate facial acne vulgaris. Limitations of Use The safety of TAZORAC Gel use on more than 20% body surface area has not been established.
Source: US FDA prescribing information
Tazarotene is a retinoid prodrug which is converted to its active form, the carboxylic acid of tazarotene, by deesterification. Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARγ, but shows relative selectivity for RARβ, and RARγ and may modify gene expression. The clinical significance of these findings for the treatment of plaque psoriasis and facial acne vulgaris is unknown.
Source: US FDA prescribing information
TAZORAC Gel is for topical use only. TAZORAC Gel is not for ophthalmic, oral, or intravaginal use. Avoid accidental transfer of TAZORAC Gel into eyes, mouth, or other mucous membranes. If contact with mucous membranes occurs, rinse thoroughly with water. Wash hands thoroughly after application. Apply a thin layer of TAZORAC Gel only to the affected area once daily in the evening. Not for ophthalmic, oral, or intravaginal use. If contact with eyes occurs, rinse thoroughly with water.
Source: US FDA prescribing information
TAZORAC Gel is contraindicated in: Pregnancy. Retinoids may cause fetal harm when administered to a pregnant female. Individuals who have known hypersensitivity to any of its components. Pregnancy. Hypersensitivity
Source: US FDA prescribing information
Embryofetal Toxicity: TAZORAC Gel contains tazarotene, which is a teratogen. TAZORAC Gel is contraindicated in pregnancy. Females of child-bearing potential should have a negative pregnancy test within 2 weeks prior to initiating treatment and use an effective method of contraception during treatment. Local Irritation: Excessive pruritus, burning, skin redness or peeling can occur. If these reactions occur, discontinue until the integrity of the skin has been restored, or consider reducing dosing frequency or in the case of psoriasis, consider switching to the lower concentration. TAZORAC Gel should not be used on eczematous skin, as it may cause severe irritation. Photosensitivity and Risk for Sunburn: Avoid exposure to sunlight, sunlamps, and weather extremes. Wear sunscreen daily.
Source: US FDA prescribing information
The following serious adverse reactions are discussed in more detail in other sections of the labeling: • Embryofetal toxicity • Photosensitivity and Risk of Sunburn Plaque Psoriasis: Most common adverse reactions occurring in 10 to 30% of patients are pruritus, burning/stinging, erythema, worsening of psoriasis, irritation, and skin pain. Acne Vulgaris: Most common adverse reactions occurring in 10 to 30% of patients are desquamation, burning/stinging, dry skin, erythema and pruritus.
Source: US FDA prescribing information
No formal drug-drug interaction studies were conducted with TAZORAC Gel. In a trial of 27 healthy female subjects between the ages of 20–55 years receiving a combination oral contraceptive tablet containing 1 mg norethindrone and 35 mcg ethinyl estradiol, concomitant use of tazarotene administered as 1.1 mg orally (mean ± SD C max and AUC 0-24 of tazarotenic acid were 28.9 ± 9.4 ng/mL and 120.6 ± 28.5 ng • hr/mL, respectively) did not affect the pharmacokinetics of norethindrone and ethinyl estradiol over a complete cycle. The impact of tazarotene on the pharmacokinetics of progestin only oral contraceptives (i.e., minipills) has not been evaluated.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F). Excursions permitted from 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
14 presentations of Tazarotene, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Tazarotene 0.1% creamTopicalGeneric name | — | US FDA | Available on request |
| Tazarotene 0.05% creamTopicalGeneric name | — | US FDA | Available on request |
| Tazarotene 0.1% gelTopicalGeneric name | — | US FDA | Available on request |
| Tazarotene 0.05% gelTopicalGeneric name | — | US FDA | Available on request |
| Tazarotene 0.05% gelCutaneousGeneric name | — | US FDA | Available on request |
| Tazarotene 0.1% gelCutaneousGeneric name | — | US FDA | Available on request |
| Tazorac 0.005% creamCutaneous | Almirall | US FDA | Available on request |
| Tazorac 0.01% creamCutaneous | Almirall | US FDA | Available on request |
| Tazorac 0.05% gelCutaneous | Almirall | US FDA | Available on request |
| Tazorac 0.1% gelCutaneous | Almirall | US FDA | Available on request |
| Arazlo 0.045% lotionTopical | Bausch Health | US FDA | Available on request |
| Fabior 0.1% foamTopical | Mayne Pharma | US FDA | Available on request |
| Tazarotene 0.1% foamTopicalGeneric name | — | US FDA | Available on request |
| Trilitas 0.1% gelTopical | Perfero Pharma | US FDA | Available on request |
4 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 13 June 1997 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Tazarotene in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 14 presentations of Tazarotene and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 4 brand names for Tazarotene, including Arazlo, Fabior, Tazorac, Trilitas.
Yes. The US FDA first approved Tazarotene on 13 June 1997, according to Drugs@FDA.
No listed presentation of Tazarotene is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tazarotene is classified under ATC code D05AX05 (Tazarotene).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.